[go: up one dir, main page]

DE60130030D1 - Verfahren zur behandlung von glaukom - Google Patents

Verfahren zur behandlung von glaukom

Info

Publication number
DE60130030D1
DE60130030D1 DE60130030T DE60130030T DE60130030D1 DE 60130030 D1 DE60130030 D1 DE 60130030D1 DE 60130030 T DE60130030 T DE 60130030T DE 60130030 T DE60130030 T DE 60130030T DE 60130030 D1 DE60130030 D1 DE 60130030D1
Authority
DE
Germany
Prior art keywords
treating glaucoma
intraocular pressure
decreasing
accommodation
improving
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60130030T
Other languages
English (en)
Other versions
DE60130030T2 (de
Inventor
John J Egan
Dilip Wagle
Sara Vasan
Martin Gall
Stanley C Bell
Edmond J Lavoie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synvista Therapeutics Inc
Original Assignee
Alteon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alteon Inc filed Critical Alteon Inc
Application granted granted Critical
Publication of DE60130030D1 publication Critical patent/DE60130030D1/de
Publication of DE60130030T2 publication Critical patent/DE60130030T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60130030T 2000-12-29 2001-12-28 Verfahren zur behandlung von glaukom Expired - Fee Related DE60130030T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US25942600P 2000-12-29 2000-12-29
US259426P 2000-12-29
US29625701P 2001-06-06 2001-06-06
US296257P 2001-06-06
US30741801P 2001-07-24 2001-07-24
US307418P 2001-07-24
PCT/US2001/049550 WO2002053158A1 (en) 2000-12-29 2001-12-28 Method for treating glaucoma ib

Publications (2)

Publication Number Publication Date
DE60130030D1 true DE60130030D1 (de) 2007-09-27
DE60130030T2 DE60130030T2 (de) 2008-04-30

Family

ID=27401231

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60130030T Expired - Fee Related DE60130030T2 (de) 2000-12-29 2001-12-28 Verfahren zur behandlung von glaukom

Country Status (9)

Country Link
US (1) US7432254B2 (de)
EP (1) EP1353669B1 (de)
JP (1) JP2004520329A (de)
AT (1) ATE369856T1 (de)
AU (1) AU2002241670B2 (de)
CA (1) CA2433346A1 (de)
DE (1) DE60130030T2 (de)
MX (1) MXPA03005922A (de)
WO (1) WO2002053158A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU780205B2 (en) * 2000-02-23 2005-03-10 Alteon Inc. Thiazolium compounds and treatments of disorders associated with protein aging
JP2004504348A (ja) * 2000-07-13 2004-02-12 アルテオン　インコーポレーテッド 線維症性疾患または他の適応症ｉｃを治療する方法
US7049333B2 (en) 2002-06-04 2006-05-23 Sanofi-Aventis Deutschland Gmbh Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis
CN100349881C (zh) * 2003-04-02 2007-11-21 深圳市东阳光实业发展有限公司 取代五元氮杂环盐类化合物及其治疗蛋白老化相关疾病的用途
US20050014747A1 (en) * 2003-04-18 2005-01-20 Emily Reinhard Dihydrothiazine prodrugs of thiazolium agents
MXPA06002214A (es) * 2003-08-26 2006-04-27 Ecole Polytech Liquidos ionicos basados en sales de imidazolio que incorporan una funcionalidad de nitrilo.
EP1732905A1 (de) 2004-03-31 2006-12-20 Lexicon Genetics Incorporated 2-aminomethylthiazol-5-carbonsäureamide als proteinkinasemodulatoren
US7601725B2 (en) 2004-07-16 2009-10-13 Sunesis Pharmaceuticals, Inc. Thienopyrimidines useful as Aurora kinase inhibitors
US8921406B2 (en) 2005-08-21 2014-12-30 AbbVie Deutschland GmbH & Co. KG 5-ring heteroaromatic compounds and their use as binding partners for 5-HT5 receptors
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
WO2011143524A2 (en) 2010-05-14 2011-11-17 Mallinckrodt Llc Functional, cross-linked nanostructures for tandem optical imaging and therapy

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ200429A (en) * 1981-04-30 1984-10-19 Smith & Nephew Ass Applicator for placing pharmaceutically active agent in contact with moist surface,e.g.,eye
US5140048A (en) * 1984-03-19 1992-08-18 The Rockefeller University Inhibitors of nonenzymatic cross-linking
US5017696A (en) * 1987-09-17 1991-05-21 The Rockefeller University Advanced glycosylation end products and associated methods
DK0458589T3 (da) * 1990-05-22 1995-04-03 R Tech Ueno Ltd Behandling af okulær hypertension med en okulær synergistisk kombination
NZ239161A (en) * 1990-07-31 1994-01-26 Smithkline Beecham Corp Substituted [1h-imidazol-5-yl] alkanoic acid derivatives; medicaments,
US5153205A (en) * 1990-10-01 1992-10-06 Merck & Co., Inc. Method to reduce introacular pressure without causing miosis
US5300031A (en) * 1991-06-07 1994-04-05 Liebel-Flarsheim Company Apparatus for injecting fluid into animals and disposable front loadable syringe therefor
US5656261A (en) * 1995-01-18 1997-08-12 The Picower Institute For Medical Research Preventing and reversing advanced glycosylation endproducts
NO315930B1 (no) * 1995-01-18 2003-11-17 Picower Inst For Medical Res T Anvendelse av tiazoliumforbindelser ved fremstilling av farmasöytiske preparater, preparater som inneholder forbindelsene, samt nyetiazoliumforbindelser
ES2203677T3 (es) * 1995-01-18 2004-04-16 Alteon, Inc. Uso de compuestos de tiazolio para prevenir y invertir la formacion de productos finales de glicosilacion avanzada.
US5744451A (en) * 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
US5854000A (en) * 1995-11-15 1998-12-29 Alteon Inc. Methods for measurement predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts
US6121300A (en) * 1998-11-10 2000-09-19 Wagle; Dilip R. Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium salts
WO2002096318A2 (en) * 2001-05-30 2002-12-05 Alteon, Inc. Method for treating glaucoma v
US6713498B2 (en) * 2001-05-30 2004-03-30 Alteon Incorporated Method for treating glaucoma VI
US6596745B2 (en) * 2001-05-30 2003-07-22 Alteon, Inc. Method for treating fibrotic diseases with azolium chroman compounds

Also Published As

Publication number Publication date
US7432254B2 (en) 2008-10-07
AU2002241670B2 (en) 2006-08-17
MXPA03005922A (es) 2004-05-04
WO2002053158A1 (en) 2002-07-11
EP1353669B1 (de) 2007-08-15
DE60130030T2 (de) 2008-04-30
CA2433346A1 (en) 2002-07-11
EP1353669A4 (de) 2005-10-19
JP2004520329A (ja) 2004-07-08
US20020160993A1 (en) 2002-10-31
EP1353669A1 (de) 2003-10-22
ATE369856T1 (de) 2007-09-15

Similar Documents

Publication Publication Date Title
WO2002053101A3 (en) Method for treating fibrotic diseases or other indications
WO2002096318A3 (en) Method for treating glaucoma v
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
ATE343388T1 (de) Pde-v hemmer zur behandlung von morbus parkinson
ATE254461T1 (de) Behandlung von augenschmerzen
BR0310047A (pt) Análogos de 8-azaprostaglandina como agentes para diminuição de pressão intra-ocular
BG106825A (en) Substituted oxazolidinones and their use in the field of blood coagulation
ATE412646T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
ATE359794T1 (de) 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes
ATE399782T1 (de) Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen
ATE369856T1 (de) Verfahren zur behandlung von glaukom
DE69116380D1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
DE3872701D1 (de) Prostaglandin-derivate zur behandlung von glaucoma oder augenueberdruck.
WO2002096362A3 (en) Method for treating fibrotic diseases or other indications vi
DE59600683D1 (de) Verwendung von Trospiumchlorid zur Herstellung eines Arzneimittels zur Behandlung von Blasenkrankheiten
WO2002102978A3 (en) Human growth hormone antagonists
EP1274414A4 (de) Nasale verabreichung von mitteln zur behandlung von gastroparese
DE69534620D1 (de) Verfahren zur behandlung von augenerkrankungen
ATE161725T1 (de) Verwendung von phosphatdiestern zur behandlung von erkrankungen der retina
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
ATE262330T1 (de) Verwendung eines nitroxids oder seiner prodrugs zur prophylaktischen und therapeutischen behandlung von krebs
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
ATE330596T1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
DE69518706D1 (de) Verwendung von Diphenylethanderivaten zur Herstellung eines Arzneimittels zur Behandlung von Glaukom
ATE344662T1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee